Baseline characteristics of the cyclophosphamide/total body irradiation cohort
| . | Tac/Mtx . | Tac/Sir/Mtx . | Tac/Sir . | P . |
|---|---|---|---|---|
| Sample size | 216 | 136 | 136 | |
| Median age, y (range) | 41 (18, 60) | 43 (19, 63) | 43 (19, 60) | .44 |
| Sex, female | 96 (44) | 51 (38) | 65 (48) | .21 |
| Donor-recipient sex match | ||||
| M-M | 72 (33) | 56 (41) | 45 (33) | |
| M-F | 48 (22) | 29 (21) | 26 (19) | |
| F-M | 44 (20) | 25 (18) | 34 (25) | |
| F-F | 52 (24) | 26 (19) | 31 (23) | |
| Stem cell source | ||||
| Peripheral blood stem cells | 130 (60) | 76 (56) | 133 (98) | <.001 |
| Bone marrow | 86 (40) | 60 (44) | 3 (2) | |
| HLA match | ||||
| Matched, unrelated | 77 (35) | 88 (65) | 59 (43) | <.001 |
| Matched, related | 118 (55) | 10 (7) | 73 (54) | |
| Mismatched | 21 (10) | 38 (28) | 4 (3) | |
| Second or subsequent transplantation | 12 (6) | 4 (3) | 4 (3) | .38 |
| Year of transplantation ≥ 2002 | 146 (68) | 94 (69) | 136 (100) | <.001 |
| Disease | ||||
| AML | 86 (40) | 49 (36) | 57 (42) | — |
| ALL | 36 (17) | 25 (18) | 9 (7) | |
| CML | 37 (17) | 25 (18) | 27 (20) | |
| MDS | 23 (11) | 16 (12) | 14 (10) | |
| NHL/HL | 22 (10) | 16 (12) | 21 (16) | |
| Other | 12 (6) | 5 (4) | 8 (6) | |
| Transplantation risk–low | 54 (25) | 25 (18) | 37 (27) | .19 |
| Acute GVHD | ||||
| Grade II-IV | 81 (40) | 41 (32) | 28 (21) | .001 |
| Grade III-IV | 37 (18) | 22 (17) | 8 (6) | .002 |
| Chronic GVHD | 63 (55) | 33 (57) | 60 (59) | .83 |
| . | Tac/Mtx . | Tac/Sir/Mtx . | Tac/Sir . | P . |
|---|---|---|---|---|
| Sample size | 216 | 136 | 136 | |
| Median age, y (range) | 41 (18, 60) | 43 (19, 63) | 43 (19, 60) | .44 |
| Sex, female | 96 (44) | 51 (38) | 65 (48) | .21 |
| Donor-recipient sex match | ||||
| M-M | 72 (33) | 56 (41) | 45 (33) | |
| M-F | 48 (22) | 29 (21) | 26 (19) | |
| F-M | 44 (20) | 25 (18) | 34 (25) | |
| F-F | 52 (24) | 26 (19) | 31 (23) | |
| Stem cell source | ||||
| Peripheral blood stem cells | 130 (60) | 76 (56) | 133 (98) | <.001 |
| Bone marrow | 86 (40) | 60 (44) | 3 (2) | |
| HLA match | ||||
| Matched, unrelated | 77 (35) | 88 (65) | 59 (43) | <.001 |
| Matched, related | 118 (55) | 10 (7) | 73 (54) | |
| Mismatched | 21 (10) | 38 (28) | 4 (3) | |
| Second or subsequent transplantation | 12 (6) | 4 (3) | 4 (3) | .38 |
| Year of transplantation ≥ 2002 | 146 (68) | 94 (69) | 136 (100) | <.001 |
| Disease | ||||
| AML | 86 (40) | 49 (36) | 57 (42) | — |
| ALL | 36 (17) | 25 (18) | 9 (7) | |
| CML | 37 (17) | 25 (18) | 27 (20) | |
| MDS | 23 (11) | 16 (12) | 14 (10) | |
| NHL/HL | 22 (10) | 16 (12) | 21 (16) | |
| Other | 12 (6) | 5 (4) | 8 (6) | |
| Transplantation risk–low | 54 (25) | 25 (18) | 37 (27) | .19 |
| Acute GVHD | ||||
| Grade II-IV | 81 (40) | 41 (32) | 28 (21) | .001 |
| Grade III-IV | 37 (18) | 22 (17) | 8 (6) | .002 |
| Chronic GVHD | 63 (55) | 33 (57) | 60 (59) | .83 |
M indicates male; F, female; AML, acute myeloid leukemia; ALL, acute lymphobastic leukemia; CML, chronic myeloid leukemia; CLL, chronic lymphocytic leukemia; MDS, myelodysplastic disorder; NHL, non-Hodgkin lymphoma; HD, Hodgkin disease; and GVHD, graft-versus-host disease. (The rate of acute GVHD is crude and does not include patients who died prior to day 30.)